Modified immune cells target untreatable lupus in groundbreaking trial
NCT ID NCT06585514
First seen Nov 01, 2025 · Last updated Apr 17, 2026 · Updated 24 times
Summary
This early-phase study is testing a new cell therapy for people with severe lupus that hasn't responded to standard treatments. Researchers will give participants a one-time infusion of their own genetically modified immune cells (called CD19 CAR T cells) designed to attack the faulty B cells thought to drive lupus. The main goals are to find a safe dose and see if this approach can effectively control the disease in 18 children and adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Conditions
Explore the condition pages connected to this study.